If you have any questions, please call 1-866-912-4726.
 
 

Jointly Provided by Advancing Knowledge in Healthcare, Inc. and CMEducation Resources, LLC

 

Supported by an Independent Educational Grant from Sanofi and Regeneron Pharmaceuticals

 

  

YEAR 2016 CARDIOVASCULAR MILESTONE CME ACTIVITIES
                   

A Year 2016 Target-to-Therapy, Evidence-to-Practice Update for the Cardiovascular, Lipid, and Atherosclerosis Specialist

Jointly Provided by

Advancing Knowledge in Healthcare, Inc. and CMEducation Resources, LLC

APPLYING LDL-TARGETED THERAPIES FOR CV RISK REDUCTION TO THE FRONT LINES  OF CARDIOVASCULAR, DIABETES, AND INTERNAL MEDICINE PRACTICE

 

Practical, Patient-Centric Approaches to LDL Lowering: Focus on Case-Based Application of Multimodal Approaches  to LDL Management Across the Hypercholesterolemic Morbidity Continuum: Diabetes, Statin Intolerance, and Poorly Responsive Patients with Elevated LDL

 

FOCUS ON MANAGEMENT OF PRIMARY AND FAMILIAL HYPERCHOLESTEROLEMIA

  

Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disease characterized by markedly elevated plasma concentrations of low-density lipoprotein (LDL) cholesterol typically well above the 95th percentile for age and sex. Because HeFH is not only relatively common and associated with a high risk of early coronary artery disease (CAD) but is easily treatable with LDL-C–lowering strategies, this genetic disorder meets the World Health Organization (WHO) criteria for systematic screening.

   

FH is one of the most frequent monogenic hereditary disorders in the general population. The frequency of heterozygotes is approximately one per 500 individuals in most countries. However, some populations around the world such as French Canadians, Afrikaners in South Africa, Lebanese and Finna have a much higher prevalence due to a founder effect. It has been estimated that there are 10,000,000 people with FH worldwide. Of these, less than 10% are diagnosed, and less than 25% are treated with LDL-lowering drugs. The risk factors of premature CVD in this population are characterized by a constellation of adverse biomarkers, and in addition to genetic testing, a number of evaluations are recommended to detect subclinical atherosclerotic vascular disease

   

FH is a world public health problem due to the high incidence of premature (<55 years in men and <65 years in women) cardiovascular disease, mainly CHD, and the resulting reduction in the life expectancy observed in many families with FH.   

Approximately, 85% of males and 50% of females will suffer a coronary event before 65 years old if they are not treated. The incidence of non-fatal CAD in patients with FH as compared to those in the general population is illustrated below:

    

This program will focus on optimizing the scientific understanding, advances, and management—including risk stratification, assessment, new targets, mechanistic paradigms, and LDL lowering—in patients with primary or familial hypercholesterolemia (FH). Internationally known experts in FH will discuss hypercholesterolemia, the biology of LDL and LDL- metabolism and catabolism, and the emerging science and medicine LDL-focused management of hyperlipidemia, atherosclerosis and CV risk reduction.

     

This scientifically rigorous, expert-generated CME program of national scope will address landmark clinical trials, mechanisms of atherosclerotic heart disease, novel LDL targets and therapies, new translational dimensions of applying advances in LDL reduction to the patient population and CV risk, disease burden in patients with FH and severe, primary hyperlipidemia.